letters
Blocking microglial pannexin-1 channels alleviates
morphine withdrawal in rodents
Nicole E Burma1,2, Robert P Bonin3, Heather Leduc-Pessah1,2, Corey Baimel2, Zoe F Cairncross1,2,
Michael Mousseau1,2, Jhenkruthi Vijaya Shankara4, Patrick L Stemkowski2, Dinara Baimoukhametova2,
Jaideep S Bains2, Michael C Antle2,4, Gerald W Zamponi2, Catherine M Cahill5, Stephanie L Borgland2,
Yves De Koninck6 & Tuan Trang1,2
Opiates are essential for treating pain, but termination of autonomic and somatic withdrawal signs in morphine- but not
opiate therapy can cause a debilitating withdrawal syndrome saline-treated rats (Supplementary Fig. 1b), the overall severity of
in chronic users. To alleviate or avoid the aversive symptoms which was expressed as a cumulative withdrawal score (Fig. 1a). In
of withdrawal, many of these individuals continue to use morphine-treated rats, CD11b immunoreactivity was significantly
opiates1–4. Withdrawal is therefore a key determinant of opiate elevated within the spinal dorsal horn, indicating that spinal microglia
use in dependent individuals, yet its underlying mechanisms are activated by morphine treatment (Fig. 1b and Supplementary
are poorly understood and effective therapies are lacking. Here, Fig. 2). Depletion of spinal lumbar microglia by intrathecal injec-
we identify the pannexin-1 (Panx1) channel as a therapeutic tions of a saporin (Sap)-conjugated antibody to Mac1 (Mac1–Sap;
target in opiate withdrawal. We show that withdrawal from 20 µg) decreased withdrawal behaviors (Supplementary Fig. 1b)
morphine induces long-term synaptic facilitation in lamina I and attenuated the severity of withdrawal (Fig. 1a) without affecting
and II neurons within the rodent spinal dorsal horn, a principal morphine antinociception (Fig. 1c). By contrast, intrathecal injec-
site of action for opiate analgesia. Genetic ablation of Panx1 tion of a nontargeting Sap (20 µg) control had no effect on spinal
in microglia abolished the spinal synaptic facilitation and CD11b immunoreactivity (Fig. 1b) or naloxone-induced morphine
ameliorated the sequelae of morphine withdrawal. Panx1 withdrawal (Supplementary Fig. 1b).
is unique in its permeability to molecules up to 1 kDa in size In the central nervous system, Panx1 channels are expressed on
and its release of ATP5,6. We show that Panx1 activation neurons and glia7,8. Flow cytometric analysis of adult lumbar spi-
drives ATP release from microglia during morphine withdrawal nal cord homogenates revealed that morphine treatment resulted in
and that degrading endogenous spinal ATP by administering elevated Panx1 expression on CD11b-positive cells (i.e., microglia)
apyrase produces a reduction in withdrawal behaviors. but not CD11b-negative cells (i.e., neurons and astrocytes) (Fig. 1d
Conversely, we found that pharmacological inhibition of and Supplementary Fig. 3). We acutely isolated CD11b-positive cells
ATP breakdown exacerbates withdrawal. Treatment with from the spinal cord of morphine- or saline-treated rats and assessed
a Panx1-blocking peptide (10panx) or the clinically used Panx1 channel function by measuring BzATP-evoked uptake of YO-
broad-spectrum Panx1 blockers, mefloquine or probenecid, PRO-1 dye, an indicator of Panx1 channel activation9,10. YO-PRO-1
suppressed ATP release and reduced withdrawal severity. uptake was significantly greater in CD11b-positive cells isolated from
Our results demonstrate that Panx1-mediated ATP release morphine-treated rats (Fig. 1e). This response was blocked by 10panx
from microglia is required for morphine withdrawal in rodents (10 µM)5,11 but was not affected by a scrambled peptide (scrpanx)
and that blocking Panx1 alleviates the severity of withdrawal (Fig. 1e). Both the increase in Panx1 protein expression
without affecting opiate analgesia. (Supplementary Fig. 4a) and YO-PRO-1 uptake (Fig. 1f) were reca-
pitulated in a BV-2 microglial-like cell line12 exposed to morphine
We investigated the mechanisms underlying opiate withdrawal by for 5 d in vitro. Dye uptake was further potentiated in the presence of
administering an opioid receptor antagonist (naloxone, 2 mg per naloxone (10 µM) (Fig. 1f) and blocked by 10panx (10 µM) (Fig. 1g).
kg body weight (mg/kg) intraperitoneally (i.p.)) to rats chronically Application of extracellular solution (ECS) as a vehicle control for
treated for 5 d with systemic morphine sulfate (MS, Supplementary BzATP did not evoke dye uptake (Fig. 1f). Moreover, treatment of
Fig. 1a). Naloxone administration precipitated a spectrum of cultured BV-2 cells with morphine and CTAP (a selective µ-receptor
1Department of Comparative Biology and Experimental Medicine, University of Calgary, Calgary, Alberta, Canada. 2Department of Physiology and Pharmacology,
Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 3Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of
Toronto, Toronto, Ontario, Canada. 4Department of Psychology, University of Calgary, Calgary, Alberta, Canada. 5Department of Anesthesiology and Perioperative Care,
University of California Irvine, Irvine, California, USA. 6Department of Psychiatry and Neuroscience, Institut Universitaire en santé mentale de Québec, Université
Laval, Ville de Québec, Québec, Canada. Correspondence should be addressed to T.T. (trangt@ucalgary.ca)
Received 7 July 2016; accepted 8 January 2017; published online 30 January 2017; corrected online 15 February 2017; doi:10.1038/nm.4281
nature medicine VOLUME 23 | NUMBER 3 | MARCH 2017 355
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
letters
a b d
***
**** 106
105
104
103
102
101
antagonist) together prevented the increase in Panx1 expression and in the accelerating rotarod test was not altered in these microglial
function (Supplementary Fig. 4a,c), whereas repeated administration Panx1-deficient mice (Supplementary Fig. 5c). Spinal microglia iso-
of the synthetic µ-receptor agonist peptide DAMGO mimicked the lated from adult microglial Panx1-deficient mice (7 d after tamoxifen
effects of morphine on Panx1 (Supplementary Fig. 4b,d). injection in Cx3cr1-CreERT2::Panx1flx/flx) showed impaired YO-PRO-3
The observation that naloxone potentiates Panx1 activity in mor- uptake (Supplementary Fig. 5d) but normal P2X7 receptor (P2X7R)
phine-treated microglia led us to examine whether microglial Panx1 function as measured by BzATP-evoked Ca2+ influx (Supplementary
channels might contribute to naloxone-induced morphine withdrawal Fig. 5e). Morphine antinociception and morphine-induced spinal
behaviors. We tested this possibility by intrathecally administering microglial reactivity remained notably intact in Panx1-deficient mice
10panx (10 µg) to morphine-treated rats 60 min before naloxone (Fig. 2b,c). However, when challenged with naloxone after morphine
challenge and found significantly lower withdrawal scores than in treatment, Panx1-deficient mice showed a significantly lower with-
morphine-treated rats injected with scrpanx (Fig. 2a). To determine drawal score than morphine-treated Panx1-expressing mice (litter-
whether the requisite Panx1 is expressed on microglia, we created mate vehicle-injected Cx3cr1-CreERT2::Panx1flx/flx mice) (Fig. 2d and
transgenic mice with a tamoxifen-dependent deletion of Panx1 in Supplementary Fig. 6).
cells expressing the chemokine C-X3-C motif receptor CX CR Cell turnover rates differ between central and peripheral CX CR -
3 1 3 1
(Cx3cr1-CreERT2::Panx1flx/flx). We confirmed in the lumbar spinal expressing populations13. Therefore, in another cohort of Cx3cr1-
cord that the CreERT2 reporter eYFP was localized to CD11b-positive CreERT2::Panx1flx/flx mice, morphine injections were initiated 28 d
cells (Supplementary Fig. 5a) and that there was a microglia-specific after tamoxifen treatment to allow for repopulation of peripheral but
reduction in Panx1 expression in tamoxifen-treated Cx3cr1- not central CX CR -expressing cells. In this cohort of Panx1-deficient
3 1
CreERT2::Panx1flx/flx mice (Supplementary Fig. 5b). Performance mice, the reduction in morphine withdrawal was comparable to that
356 VOLUME 23 | NUMBER 3 | MARCH 2017 nature medicine
1xnaP
101 102 103 104 105 CD11b
IFM 1xnaP
CTR MS/Mac1–Sap
CTR MS MS MS/Sap CD11b–
5
*
4
CD11b 3 NS
MS/Mac1–Sap MS/Sap
2
1
C M TR S/M M ac S 1–Sa M p S/Sap 1 T 2 im 3 e (d 4 ) 5 CTR MS CTR MS
)s(
ycnetal
lawardhtiw
lamrehT
c
****
****
****
)%(
aera
RI-b11DC
50
40
30
20
10
0 MS C ( T wi R tho M M ut S S / N M L a X c ) 1–Sa M p S/Sap
erocs
lawardhtiW
**** CD11b– CD11b+ CD11b+
15 3.5
**** **** 3.0
NS 2.5
10 2.0
1.5
5 1.0
0.5
0.0
0
e f g
CTR
BzATP MS
0 min 30 min MS/NLX ECS BzATP *
BzATP R BzATP * CTR T MS C MS/10panx MS/scrpanx NS
S M
X
CD11b NL S/ M
)enilesab %(
ekatpu
eyD
CTR MS
)enilesab %(
ekatpu
eyD
2,500 **** 1,000 400
2,000 800 **** 300 600 1,500 **
400 1,000 200
200 500
0 100 0 0
Tim
1
e
0
(m
2
i
0
n)
30 MS/10pa
M
n
S/
x scrp
C
a
T
n
R
x /10panx 0
Tim
1
e
0
(m
2
i
0
n)
30
)enilesab %(
ekatpu
eyD
)enilesab %(
ekatpu
eyD
)enilesab %(
ekatpu
eyD
**** 250 300 ****
200 200 150
100
100
50
0 0 CTR MS CTR M
C
S TR/NLX MS/NLX CTR/scrpa
M
n
S
x /scrp
C
a
T
n
R
x /10pa
M
n
S
x /10panx
Figure 1 Repeated morphine treatment increases microglial Panx1 expression and activity. (a) Quantification of naloxone-induced composite behavioral
withdrawal scores in rats treated for 5 d with saline (CTR, n = 5) or morphine sulfate (MS, n = 7), compared to MS-treated rats receiving intrathecal
Mac1–Sap (MS/Mac1–Sap, n = 5) or Sap alone (n = 7). One-way ANOVA (F3,20 = 27.95) and Bonferroni post hoc test. (b) Representative images (left)
and quantification (right) of CD11b immunoreactivity (IR) in spinal dorsal horn sections of rats treated with CTR or MS with or without naloxone (NLX),
Mac1–Sap or Sap. n = 7–9 spinal cord sections analyzed. One-way ANOVA (F4,35 = 50.96) and Sidak post hoc test. (c) Quantification of MS-induced
antinociception in the thermal tail flick test in rats treated with CTR or MS with or without Mac1–Sap or Sap over 5 d. n = 4 or 5 rats per group.
Two-way repeated measures ANOVA (significant effect of treatment F3,14 = 42.26). (d) Left, flow cytometric analysis from control rat representing
gating parameters for CD11b− (black) and CD11b+ (yellow) populations used to calculate mean fluorescence intensity (MFI) of Panx1 labeling. Right,
quantification of Panx1 expression in CD11b− and CD11b+ spinal cord cell populations obtained from CTR- or MS-treated rats. MS MFI values are
normalized to levels of control cells. n = 6 experimental replicates with 3 animals per group. One-way ANOVA (F3,20 = 6.02) and Sidak post hoc test.
(e) Left, individual traces of BzATP-evoked YO-PRO-1 uptake in CD11b+ cultured spinal microglia from adult rats treated with CTR or MS in the
presence or absence of 10panx or scrpanx. Inset, anti-CD11b staining to identify microglial cells (arrowheads) in the acutely isolated mixed culture
preparation (Online Methods). Right, quantification of total dye uptake 30 min after BzATP application in CTR (n = 32 cells), MS (n = 26), MS/10panx
(n = 22), MS/scrpanx (n = 20) and CTR/10panx (n = 29) conditions. One-way ANOVA (F5,146 = 9.89) and Sidak post hoc test. (f) Representative images
(left), individual traces (middle) and quantification at 30 min (right) of BzATP-evoked dye uptake in BV-2 cells treated for 5 d in vitro with CTR,
MS or MS with NLX pretreatment (MS/NLX). ECS, control extracellular solution. n = 5 (ECS), 12 (BzATP CTR), 9 (MS and MS/NLX) or 8 (CTR/NLX)
experiments per condition. One-way ANOVA (F5,42 = 16.42) with Sidak post hoc test. (g) Quantification of dye uptake in NLX-pre-treated BV-2 cells
(CTR- or MS-treated) at 30 min after BzATP application in the presence of scrpanx or 10panx. n = 7 or 8 experiments per condition. ANOVA (F3,27 =
19.02). Error bars, s.e.m; each data point represents an individual animal or experiment. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001;
NS, nonsignificant. Scale bars, 50 µm (b,e,f).
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
letters
a b c d e
CTR/VEH CTR/TAMX Cx3cr1-CreERT2::Panx1flx/flx Panx1flx/flx
MS/VEH MS/TAMX CTR/VEH MS/VEH **** 5 **** **** 4 *** **** * NS
3 **** CD11b **** CTR/TAMX MS/TAMX
2
1
0 T 3 i 0 me 6 0 (m 9 in 0 ) 1201 T 2 im 3 e ( 4 d) 5 CT V R EH MS C T T A R MX MS CT V R EH MS C T T A 7 R M d X MS C T T 2 A R 8 M d X MS C T T A R MX MS scrpanx 1 / 0 V p E a s H n cr x/ p V a E nx H 1 / 0 T p A a M nx X /TA MX
observed in mice receiving morphine injections 7 d after tamoxifen ecal injection of 10panx before naloxone challenge significantly
treatment (Fig. 2d), suggesting that Panx1 on microglia, not periph- attenuated morphine withdrawal in Panx1-expressing mice (Fig. 2e)
eral CX CR -expressing cells, is required for morphine withdrawal. but did not further ameliorate withdrawal in Panx1-deficient mice 3 1
Furthermore, morphine withdrawal was attenuated in both male and (Fig. 2e). This loss of 10panx effect, together with the amelioration of
female Panx1-deficient mice (Supplementary Fig. 7), indicating that withdrawal in Panx1-deficient mice, implicates microglial Panx1 in
microglial Panx1 critically contributes to opiate withdrawal in both morphine withdrawal.
sexes. As another control, we administered tamoxifen to mice lacking To investigate the mechanisms underlying Panx1-mediated with-
inducible Cre recombinase (Panx1flx/flx) and found that the sever- drawal, we first measured spinal cFos expression as a cellular correlate
ity of naloxone-precipitated withdrawal was indistinguishable from of neuronal activation14. We determined that naloxone-precipitated
vehicle-treated Panx1-expressing mice (Cx3cr1-CreERT2::Panx1flx/flx) withdrawal increased the number of cFos-positive neurons within the
(Fig. 2d). Thus, tamoxifen per se does not affect morphine with- spinal dorsal horn of Panx1-expressing mice; this increase was sup-
drawal. To further investigate the requirement for microglial Panx1 pressed in mice lacking microglial Panx1 (Fig. 3a). To assess neuronal
in morphine withdrawal, we compared the actions of 10panx (10 µg) function more directly, we used a whole lumbar spinal cord prepara-
in Panx1-deficient and Panx1-expressing mice. We reasoned that if tion with intact dorsal roots15 prepared from Panx1-expressing or
the effects of 10panx were mediated by blocking Panx1 on microglia, microglial Panx1-deficient adult mice that had been treated for 5 d
they would be lost in the absence of microglial Panx1. Indeed, intrath- with saline or morphine. We electrically stimulated the dorsal root to
nature medicine VOLUME 23 | NUMBER 3 | MARCH 2017 357
)s( ycnetal lawardhtiw
lamrehT
40 30
20
10
0
CTR MS M /1 S 0p M a S n /s x cr C p T an R/ x 10panx
erocs lawardhtiW 10 **** **** 8 **** 6
4
2
0
)%( aera
RI-b11DC
50 * 40 30
20
10
0
erocs lawardhtiW 50 40 30
20
10
0
erocs lawardhtiW **
Figure 2 Blocking microglial Panx1 alleviates morphine withdrawal. (a) Effect of intrathecal 10panx on naloxone-induced composite behavioral
withdrawal scores in rats treated with morphine sulfate (MS) or saline (CTR) for 5 d. n = 5–7 rats per group. One-way ANOVA (F4,23 = 38.29) with
Sidak post hoc. (b) Antinociception after a single MS injection (left) or over 5 d of MS treatment (right) in vehicle (VEH)- and tamoxifen (TAMX)-treated
Cx3cr1-CreERT2::Panx1flx/flx mice assessed using the thermal tail immersion test. n = 6 mice (CTR/VEH, MS/VEH, CTR/TAMX) or 7 (MS/TAMX). Two-way
repeated measures ANOVA (significant effect of time (F5,105 = 40.19), treatment (F3,21 = 12.13) and interaction (F15,105 = 10.55) for time course and
significant effect of treatment (F3,21 = 70.04) for daily tail withdrawal latency). (c) Representative images (left) and quantification (right) of CD11b
immunoreactivity (IR) in spinal dorsal horn sections of VEH- and TAMX-treated Cx3cr1-CreERT2::Panx1flx/flx mice after 5 d of MS or CTR treatment. Scale
bar, 100 µm. n = 12 spinal cord sections per group. One-way ANOVA (F3,44 = 5.38) with Sidak post hoc test. (d) Naloxone-precipitated withdrawal
scores in Cx3cr1-CreERT2::Panx1flx/flx mice treated with VEH or TAMX 7 or 28 d before MS withdrawal and in TAMX-treated Panx1flx/flx mice. One-way
ANOVA (F7,37 = 63.07) with Sidak post hoc. n = 5–8 mice per group. (e) Naloxone-induced withdrawal scores in MS-treated VEH and TAMX Cx3cr1-
CreERT2::Panx1flx/flx mice given intrathecal scrpanx or 10panx. n = 4 or 6 mice per group. One-way ANOVA (F3,16 = 8.01) with Sidak post hoc. Error bars,
s.e.m; each data point represents an individual animal or experiment. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; NS, nonsignificant.
CTR/VEH
MS/VEH 200 CTR/TAMX MS/TAMX VEH 175 TAMX NS
150
125
100
NLX
75
–150
Tim
15
e (
3
m
0
in
4
)
560 CT
V
R
EH
MS C
T
T
A
R
MX
MS VEH TA MX
noitces
rep
sllec
RI-soFc
)enilesab
%( aera
PSPf
a b
200 175
150
125
100
75
CTR MS CTR MS –150 15304560
VEH TAMX Time (min)
)enilesab
%( aera
PSPf
c d e
CTR/VEH MS/VEH 70 **** *** 250 60 200 50
40 ** 150
CTR/TAMX MS/TAMX 30 100
20 L1-L3 50 10
0 0
)enilesab
%( aera
PSPf
** * 250
200
150
100 50
0
)enilesab
%(
aera PSPf
Figure 3 Genetic ablation of microglial Panx1 prevents naloxone-induced synaptic facilitation in spinal lamina I–II dorsal horn neurons of morphine-
treated mice. (a) Representative images (left) and quantification (right) of cFos-immunoreactive (cFos-IR) neurons (arrowheads) in spinal dorsal horn
(SDH) of vehicle (VEH)- and tamoxifen (TAMX)-treated Cx3cr1-CreERT2::Panx1flx/flx mice after 5 d of morphine sulfate (MS) or saline (CTR) treatment.
Insets, magnified view of indicated cFos-IR neurons. Scale bars 50 µm (main) and 25 µm (inset). n = 13 (CTR/VEH), 11 (MS/VEH and CTR/TAMX)
or 10 (MS/TAMX) spinal cords. One-way ANOVA (F3,41 = 29.75) with Sidak post hoc. (b) Left, fPSPs induced by naloxone (NLX) application in mice
treated as in a. n = 7 (CTR/VEH and CTR/TAMX), 6 (MS/VEH) or 5 (MS/TAMX). Right, schematic of stimulation and recording setup for electrophysiology
experiments. (c) Average fPSP area over the last 5 min of SDH recordings in mice as in b. n = 6–7. One-way ANOVA (F3,22 = 4.73) with Sidak post hoc.
(d) Facilitation of fPSPs in lamina I–II of SDH after low-frequency electrical stimulation of dorsal roots (black arrowhead) in Cx3cr1-CreERT2::Panx1flx/flx
mice treated with VEH (n = 6) or TAMX (n = 5). (e) Average fPSP area over last 5 min of electrical facilitation experiments in Cx3cr1-CreERT2::Panx1flx/flx
mice. n = 5–6. Two-tailed t-test (t = 1.062, df = 9, P = 0.32). Error bars, s.e.m; each data point represents an individual animal or experiment.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; NS, nonsignificant.
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
letters
a b c d e
* 50 *** **** NS
NS 40
NS 30
20
10
0
CT V R EH MS C T T A R MX MS CT R MS CT R MS CT R MS A CT T R PγS MS MS/ M A S p M y S r / a A se RL67156 C V T R EH MS C M T R FQ MS C P T R RB MS
f CTR MS/PRB g h i j
MS MS/MFQ
NLX BzATP
CT R MS CT R MS CT R MS CT R MS CT R MS CT R MS CT R MS CT R F C CT R F C
MFQ PRB PRB VEH TAMX PRB
evoke postsynaptic field potentials (fPSPs) recorded from laminae I–II from Panx1-deficient mice (Fig. 4a). To test whether ATP is directly
of the spinal dorsal horn and found that bath application of naloxone released from microglia, we applied naloxone to microglia in culture.
(10 µM) produced a slow-rising facilitation of fPSPs that persisted for Supernatants of morphine-treated microglia showed increase in ATP,
at least 60 min in morphine- but not saline-treated Panx1-expressing and this increase was blocked by 10panx (Fig. 4b). Thus, naloxone
mice (Fig. 3b,c). By contrast, this response to naloxone did not occur induces the release of ATP from morphine-treated microglia via a
in morphine-treated Panx1-deficient mice (Fig. 3b,c). The absence Panx1-dependent mechanism.
of synaptic facilitation in these mutant mice was not due to a general To test whether ATP contributes to morphine withdrawal,
defect in spinal synaptic facilitation, because electrically stimulating we administered ATPγS (100 µM) intrathecally to Panx1-deficient
the dorsal roots of Panx1-deficient mice at low frequency (2 Hz) pro- mice, which display attenuated morphine withdrawal behaviors.
duced a robust and long-lasting increase in fPSPs (Fig. 3d,e). In these mice, local delivery of the ATP analog together with naloxone
Because ATP release is a key consequence of Panx1 activation6,16, challenge restored a spectrum of withdrawal behaviors; these
we asked whether Panx1-mediated ATP release occurs during with- behaviors were not observed when ATPγS was administered to
drawal. To test this, we bath-applied naloxone (10 µM) to spinal saline-treated Panx1-deficient mice (Fig. 4c). We reasoned that if
cord slices isolated from Panx1-expressing and Panx1-deficient ATP is required for morphine withdrawal, then altering endogenously
mice that had been treated for 5 d with saline or morphine. We mea- released ATP in the spinal cord might influence withdrawal behav-
sured the amount of ATP in spinal superfusates and found that the iors. In morphine-treated rats, we tested this possibility by intrathecal
level of ATP in response to naloxone was significantly higher in administration of the ATP-degrading enzyme apyrase (10 units)17,
morphine- than in saline-treated Panx1-expressing mice (Fig. 4a). which produced a notable reduction in withdrawal score (Fig. 4d).
Naloxone-induced ATP release was not observed in slices prepared Conversely, inhibiting ATP breakdown by intrathecally administering
358 VOLUME 23 | NUMBER 3 | MARCH 2017 nature medicine
erocs
lawardhtiW
* 150 * 125
100
75
50
25
0
)1–gµ
Mn(
PTA
400
300
200
100
0
)lortnoc
fo
%( esaeler
PTA
ECS NLX
*** 50 **
* 40
30
20
10
0
MS/scrpa M n S x / 10panx
erocs
lawardhtiW
50
40
30
20
10
0
erocs
lawardhtiW
**** **** ****
200 180
160 140
120
100
0 102030
Time (min)
)enilesab
%( ekatpu
eyD
200
150
100
50
0
)enilesab
%( ekatpu
eyD
*** 350
** * 300 250
200 150
100
50
0
)lortnoc
fo %(
PTA
*** 40
**** *** 30
20
10
0
erocs
lawardhtiW
)suoenatnops
h 42(
40
** **** 30
20
10
0
erocs
lawardhtiW
)suoenatnops
h 42(
40
*** ** 30
20
10
0
erocs
lawardhtiW
**
****
CT R MS CT R MS CT R MS
MFQ PRB
Figure 4 ATP released from microglial Panx1 is suppressed by mefloquine and probenecid. (a) Naloxone (NLX)-evoked ATP levels in artificial cerebral
spinal fluid (aCSF) from lumbar spinal cord slices isolated from vehicle (VEH)- or tamoxifen (TAMX)-treated Cx3cr1-CreERT2::Panx1flx/flx mice after
5 d of saline (CTR) or morphine (MS) treatment (n = 5 mice per treatment). One-way ANOVA (F3,16 = 10.30) with Sidak post hoc. (b) ATP levels in
extracellular solution (ECS) supernatant from MS or CTR-treated BV-2 cells after application of ECS or NLX and 10panx or scrpanx. n = 17 (CTR/ECS,
MS/ECS, MS/NLX, MS/10panx), 15 (CTR/NLX) or 14 (MS/scrpanx) experiments. Data are relative to CTR-treated BV-2 cells exposed to ECS from the
same experiment. One-way ANOVA (F5,91 = 6.33) with Sidak post hoc. (c) Effect of intrathecal ATPγS saline on composite withdrawal scores of TAMX-
treated mice as in a. n = 5–6 mice per group. One-way ANOVA (F3,17 = 34.04) with Sidak post hoc. (d) NLX-precipitated withdrawal scores in MS-
treated rats that received intrathecal saline (MS), apyrase (MS/Apyrase) or ARL67156 (MS/ARL67156). n = 5–6. One-way ANOVA (F2,14 = 15.19) with
Bonferroni post hoc. (e) Effect of systemic injection of vehicle (VEH, n = 5 or 7), mefloquine (MFQ, n = 4 or 5) or probenecid (PRB, n = 5 per group) on
NLX-precipitated withdrawal scores in rats that received CTR or MS for 5 d. One-way ANOVA (F5,25 = 34.91) with Sidak post hoc. (f) Individual traces
(left) and quantification after 30 min (right) of BzATP-evoked YO-PRO-3 uptake in BV-2 cells treated for 5 d in vitro with CTR or MS in the presence or
absence of MFQ or PRB. NLX was applied 10 min before baseline and was present in ECS throughout the experiment. n = 6 or 7 experiments. One-way
ANOVA (F5,32 = 6.12) with Sidak post hoc. (g) ATP levels collected in ECS supernatant after NLX application in BV-2 cells treated for 5 d in vitro with
CTR (n = 16 experiments) or MS (n = 18) alone or in the presence of MFQ (n = 15 (CTR) or 17 (MS)) or PRB (n = 14 per group). One-way ANOVA
(F7, 98 = 7.23) with Sidak post hoc. (h) Spontaneous composite behavioral withdrawal scores in mice treated with saline (CTR, n = 3) or MS (n = 5) for
5 d, compared to mice that received systemic PRB (n = 3 or 7). One-way ANOVA (F3,14 = 23.39) with Sidak post hoc. (i) Quantification of spontaneous
behavioral withdrawal scores in VEH- and TAMX-treated Cx3cr1-CreERT2::Panx1flx/flx mice that received saline (CTR) or MS for 5 d. n = 3–6. One-way
ANOVA (F3,13 = 17.43) with Sidak post hoc. (j) NLX-precipitated composite withdrawal scores in mice treated with saline (n = 6) or fentanyl citrate
(FC, n = 10) for 7 d in the presence or absence of systemic PRB (n = 6 or 15). One-way ANOVA (F3,33 = 14.87) with Sidak post hoc. Error bars, s.e.m;
each data point represents an individual animal or experiment. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; NS, nonsignificant.
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
letters
the ecto-ATPase inhibitor ARL67156 (10 nmol)18,19 exacerbated mechanisms, the potent alleviation of opiate withdrawal by clinically
morphine withdrawal (Fig. 4d). We therefore conclude that ATP is used Panx1-blocking drugs (probenecid and mefloquine) highlights
a key substrate for morphine withdrawal. the potential of our findings for immediate therapeutic translation.
P2X7R activation is a core mechanism for opening Panx1 chan- Targeting Panx1 channels may therefore represent a new clinical
nels5,10. We determined that P2X7R expression was selectively strategy for alleviating withdrawal symptoms without impairing
increased in spinal microglia isolated from morphine-dependent rats morphine analgesia.
(Supplementary Fig. 8a), and blockade of these receptors by intrathe-
cal administration of the selective P2X7R antagonist A-740003 attenu- MeTHODs
ated withdrawal (Supplementary Fig. 8b). These findings position Methods, including statements of data availability and any associated
P2X7R as an upstream signaling node through which morphine accession codes and references, are available in the online version of
potentiates Panx1 function, defining P2X7R–Panx1 as a microglial the paper.
signaling ensemble required for morphine withdrawal. Specifically
Note: Any Supplementary Information and Source Data files are available in the
targeting Panx1 while leaving P2X7R function intact could, however,
online version of the paper.
be the preferred strategy for treating opiate withdrawal.
Having established that Panx1 is crucially involved in morphine ACKNoWLEDGMENTS
withdrawal, we tested as proof of concept two clinically used broad- We thank D. Littman and W.-B. Gan (both at New York University School of
spectrum Panx1 inhibitors: probenecid, an anti-gout medication20, and Medicine) for generously providing breeding pairs for the Cx3cr1-CreERT2
mouse colony, R. Thompson (University of Calgary) for providing the Panx1flx/flx
mefloquine, an antimalarial drug21. In morphine-treated rats, systemic
mice, and F. Visser for mouse genotyping. BV-2 microglial-like cells were provided
administration of probenecid or mefloquine 60 min before naloxone by M. Tsuda (Kyushu University) and K. Biber (University of Groningen). We also
challenge significantly ameliorated morphine withdrawal (Fig. 4e thank K. Jhamandas and B. Zochodne for comments on the manuscript and the
RUN CORE Facility for access to the Nikon C1S1 confocal and A1R multiphoton and Supplementary Fig. 9a). These compounds also blocked BzATP-
microscopes. This work was supported by grants from the Vi Riddell Program for
evoked potentiation of Panx1 activation (Fig. 4f and Supplementary Pediatric Pain, Natural Sciences and Engineering Research Council of Canada
Fig. 9b) and suppressed ATP release in morphine-treated microglia (RGPIN418299) and the Rita Allen Foundation and American Pain Society to
cultures (Fig. 4g and Supplementary Fig. 9c) without altering P2X7R- T.T. Canadian Institutes of Health Research grants were also awarded to T.T.
mediated calcium responses (Supplementary Fig. 10a,b). (MOP133523), Y.D.K. (MOP12942) and G.W.Z. (FDN143336). N.E.B. is supported
by a Hotchkiss Brain Institute Doctoral Scholarship and a Queen Elizabeth II
To further extend the potential clinical utility of probenecid, we Scholarship. R.P.B., G.W.Z. and Y.D.K. hold Canada Research Chairs.
tested the actions of this compound in a model of spontaneous mor-
phine withdrawal that does not rely on naloxone challenge. Mice AUTHoR CoNTRIBUTIoNS
given a 5-d morphine treatment showed robust withdrawal behav- N.E.B. and T.T. conceived and designed the project. N.E.B., R.P.B., H.L.-P., C.B.,
Z.F.C., M.M., J.V.S., P.L.S., D.B. and C.M.C. performed the experiments. T.T.,
iors 24 h after morphine cessation, and these behaviors were attenu-
Y.D.K., S.L.B., M.C.A., G.W.Z. and J.S.B. supervised the experiments. N.E.B.,
ated by a systemic injection of probenecid (50 mg/kg, i.p.) (Fig. 4h). R.P.B., H.L.-P., M.C.A. and C.M.C. analyzed the data. N.E.B. and T.T. wrote the
Spontaneous withdrawal was also reduced in Panx1-deficient mice manuscript. All authors read and approved the manuscript.
(Fig. 4i), suggesting a common microglial Panx1-dependent mecha-
CoMPETING FINANCIAL INTERSTS
nism in both naloxone-precipitated and spontaneous withdrawal. The authors declare no competing financial interests.
Finally, we investigated the effects of probenecid on fentanyl, another
clinically used and widely abused opioid. In fentanyl-treated mice, Reprints and permissions information is available online at http://www.nature.com/
reprints/index.html.
naloxone precipitated robust withdrawal that was ameliorated by
probenecid (Fig. 4j). Taken together, the effects of probenecid and
1. Stotts, A.L. et al. A stage I pilot study of acceptance and commitment therapy for
mefloquine in alleviating opiate withdrawal open the possibility that methadone detoxification. Drug Alcohol Depend. 125, 215–222 (2012).
these, and other clinically available broad-spectrum Panx1 inhibitors, 2. Weiss, R.D. et al. Reasons for opioid use among patients with dependence on
prescription opioids: the role of chronic pain. J. Subst. Abuse Treat. 47, 140–145
have potential application in the treatment of opiate withdrawal.
(2014).
In summary, we have discovered that a substrate within the spinal 3. Frank, J.W. et al. Patients’ perspectives on tapering of chronic opioid therapy: a
cord—microglial Panx1-mediated ATP release—underlies the cel- qualitative study. Pain Med. 17, 1838–1847 (2016).
4. Yarborough, B.J.H. et al. Methadone, buprenorphine and preferences for opioid
lular and behavioral correlates of morphine withdrawal. We propose agonist treatment: a qualitative analysis. Drug Alcohol Depend. 160, 112–118
that Panx1 activation is a fundamental mechanism through which (2016).
5. Pelegrin, P. & Surprenant, A. Pannexin-1 mediates large pore formation and
microglia cause long-term synaptic facilitation in spinal lamina I–II
interleukin-1β release by the ATP-gated P2X7 receptor. EMBO J. 25, 5071–5082
neurons during withdrawal. This form of neuronal hyperexcitability (2006).
is a cardinal feature of withdrawal14,22, and we demonstrate here that 6. Sandilos, J.K. et al. Pannexin 1, an ATP release channel, is activated by caspase
cleavage of its pore-associated C-terminal autoinhibitory region. J. Biol. Chem. 287,
this central tenet of withdrawal occurs directly in the spinal cord of
11303–11311 (2012).
morphine-treated animals. Because opiate withdrawal engages both 7. Huang, Y., Grinspan, J.B., Abrams, C.K. & Scherer, S.S. Pannexin1 is expressed
spinal and supraspinal mechanisms, including the periaqueductal by neurons and glia but does not form functional gap junctions. Glia 55, 46–56
(2007).
gray14, locus coeruleus23, ventral tegmental area24–26 and nucleus 8. Iglesias, R., Dahl, G., Qiu, F., Spray, D.C. & Scemes, E. Pannexin 1: the molecular
accumbens27, descending inputs from these supraspinal regions substrate of astrocyte “hemichannels”. J. Neurosci. 29, 7092–7097 (2009).
9. Iglesias, R. et al. P2X7 receptor–pannexin1 complex: pharmacology and signaling.
may influence spinal facilitation in the intact system. However, our
Am. J. Physiol. Cell Physiol. 295, C752–C760 (2008).
isolated spinal cord preparation suggests that intrinsic spinal mecha- 10. Sorge, R.E. et al. Genetically determined P2X7 receptor pore formation regulates
nisms are sufficient for synaptic facilitation during withdrawal, and as variability in chronic pain sensitivity. Nat. Med. 18, 595–599 (2012).
11. Thompson, R.J. et al. Activation of pannexin-1 hemichannels augments aberrant
further evidence for a spinal locus of opiate action, we show that spi- bursting in the hippocampus. Science 322, 1555–1559 (2008).
nal manipulations targeting Panx1 channels or ATP levels effectively 12. Masuda, T. et al. Transcription factor IRF5 drives P2X4R+-reactive microglia gating
neuropathic pain. Nat. Commun. 5, 3771 (2014).
block or recapitulate the behavioral and cellular corollaries of with-
13. Parkhurst, C.N. et al. Microglia promote learning-dependent synapse formation
drawal. Although we do not rule out contributions from supraspinal through brain-derived neurotrophic factor. Cell 155, 1596–1609 (2013).
nature medicine VOLUME 23 | NUMBER 3 | MARCH 2017 359
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
letters
14. Bagley, E.E. et al. Drug-induced GABA transporter currents enhance GABA release 21. Iglesias, R., Spray, D.C. & Scemes, E. Mefloquine blockade of pannexin1 currents:
to induce opioid withdrawal behaviors. Nat. Neurosci. 14, 1548–1554 (2011). resolution of a conflict. Cell Commun. Adhes. 16, 131–137 (2009).
15. Bonin, R.P. & De Koninck, Y. A spinal analog of memory reconsolidation enables 22. Drdla, R., Gassner, M., Gingl, E. & Sandkühler, J. Induction of synaptic long-term
reversal of hyperalgesia. Nat. Neurosci. 17, 1043–1045 (2014). potentiation after opioid withdrawal. Science 325, 207–210 (2009).
16. Huang, Y.-J. et al. The role of pannexin 1 hemichannels in ATP release and cell–cell 23. Han, M.-H. et al. Role of cAMP response element–binding protein in the rat locus
communication in mouse taste buds. Proc. Natl. Acad. Sci. USA 104, 6436–6441 ceruleus: regulation of neuronal activity and opiate withdrawal behaviors.
(2007). J. Neurosci. 26, 4624–4629 (2006).
17. Chiang, C.Y. et al. Endogenous ATP involvement in mustard-oil-induced central 24. Koo, J.W. et al. Epigenetic basis of opiate suppression of Bdnf gene expression in
sensitization in trigeminal subnucleus caudalis (medullary dorsal horn). the ventral tegmental area. Nat. Neurosci. 18, 415–422 (2015).
J. Neurophysiol. 94, 1751–1760 (2005). 25. Vargas-Perez, H. et al. Ventral tegmental area BDNF induces an opiate-dependent-
18. Beckel, J.M. et al. Pannexin 1 channels mediate the release of ATP into the lumen like reward state in naive rats. Science 324, 1732–1734 (2009).
of the rat urinary bladder. J. Physiol. (Lond.) 593, 1857–1871 (2015). 26. Laviolette, S.R., Gallegos, R.A., Henriksen, S.J. & van der Kooy, D. Opiate state
19. Nakatsuka, T. & Gu, J.G. ATP P2X receptor–mediated enhancement of glutamate controls bi-directional reward signaling via GABAA receptors in the ventral tegmental
release and evoked EPSCs in dorsal horn neurons of the rat spinal cord. J. Neurosci. area. Nat. Neurosci. 7, 160–169 (2004).
21, 6522–6531 (2001). 27. Zhu, Y., Wienecke, C.F.R., Nachtrab, G. & Chen, X. A thalamic input to the
20. Silverman, W., Locovei, S. & Dahl, G. Probenecid, a gout remedy, inhibits pannexin nucleus accumbens mediates opiate dependence. Nature 530, 219–222
1 channels. Am. J. Physiol. Cell Physiol. 295, C761–C767 (2008). (2016).
360 VOLUME 23 | NUMBER 3 | MARCH 2017 nature medicine
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
ONLINe MeTHODs (50 mg/kg i.p., Sigma) 60 min before naloxone-precipitated withdrawal. In the
Animals. Adult male rats and mice were used (rats aged 7–8 weeks; mice aged spontaneous withdrawal experiments, mice received probenecid (50 mg/kg
8–12 weeks for behavioral experiments and 6–10 weeks for electrophysiology i.p., Sigma) 23 h after the last morphine or control injection (60 min before
experiments). Mice and rats were housed under a 12-h/12-h light/dark cycle assessment of spontaneous withdrawal) on day 6. In the fentanyl withdrawal
with ad libitum access to food and water and were randomly allocated to dif- experiments, mice received probenecid (50 mg/kg i.p., Sigma) 10 min after
ferent test groups. All experiments were approved by the University of Calgary, last fentanyl injection and 20 min before naloxone-precipitated withdrawal on
Université Laval and University of California Irvine Animal Care Committees day 7. Both mefloquine and probenecid were reconstituted in β-cyclodextrin
and are in accordance with the guidelines of the Canadian Council on Animal (Sigma), and control animals received systemic β-cyclodextrin.
Care and the US National Institutes of Health Guide for the Care of Use of
Laboratory Animals. Assessment of sensorimotor coordination. Sensorimotor coordination was
evaluated using the accelerating rotarod test (Panlab, Harvard Apparatus).
Morphine dosing paradigm and nociceptive behavioral models. Morphine All mice underwent two conditioning trials before testing. Motor behavior
sulfate (PCCA) prepared in 0.9% sterile saline solution was injected i.p. twice was analyzed 7 d after last tamoxifen or vehicle injection. In brief, mice were
daily (8 a.m. and 5 p.m.) into male Sprague-Dawley rats (weight ranging placed on a rotating rod set to gradually accelerate from 4 to 40 r.p.m. over
200–250 g, escalating doses from 10 to 45 mg/kg)28, C57BL/6 mice, male and 5 min. The trial was terminated when the mouse fell off the apparatus, and
female Cx3cr1-CreERT2::Panx1flx/flx or Panx1flx/flx mice (weight ranging 16–30 g, both time and terminal speed (r.p.m.) were recorded.
escalating doses from 7.5 to 50 mg/kg). Thermal nociceptive thresholds were
assessed using the tail-flick test (rats) and the tail-immersion test (mice). For Behavioral assessment of fentanyl withdrawal. Fentanyl citrate (West Ward
rats, an infrared thermal stimulus (Ugo Basile) was applied to the ventral Pharmaceuticals) prepared in 0.9% sterile saline solution was injected i.p. at
surface of the tail, and time latency for tail removal from the stimulus was ascending doses (day 1, 5 and 25 µg/kg at 8-h intervals; day 2, 50 µg/kg at 8-h
recorded. For mice, the distal portion of the tail was submerged in a 50 °C intervals; day 3, 75 µg/kg at 8-h intervals; day 4, 100 µg/kg at 8-h intervals; day 5,
water bath, and time latency for tail removal from the stimulus was recorded. 150 µg/kg at 8-h intervals; day 6 150 µg/kg at 4-h intervals). On day 7, mice
A maximum cutoff time was set at 10 s to prevent tissue damage. Nociceptive received two injections of fentanyl 4 h apart (150 µg/kg) and 30 min after the
measurements were taken before and 30 min after morphine injections, and second dose naloxone (10 mg/kg, Sigma) to rapidly induce opiate withdrawal.
values were normalized to daily baseline. In a subset of mouse experiments, a Control mice received an equivalent volume of 0.9% saline and were challenged
time course of morphine-induced antinociception was performed at 30, 45, 60, with naloxone on day 7. Signs of withdrawal were recorded after naloxone
90 and 120 min after a single acute injection of morphine (7.5 mg/kg). injection for a 20-min test period as described above for morphine withdrawal.
The experimenter was blind to the drug treatment groups of the mice.
Behavioral assessment of morphine withdrawal. Rats and mice received
ascending doses of morphine i.p. at 8-h intervals (rats: day 1, 10 mg/kg; day 2, Western blotting. Cultured microglia were harvested in 150 µL lysis buffer
20 mg/kg; day 3, 30 mg/kg; day 4, 40 mg/kg; mice: day 1, 7.5 and 15 mg/kg; day 2, containing 50 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 0.1% Triton-X,
20 and 25 mg/kg; day 3, 30 and 35 mg/kg; day 4, 40 and 45 mg/kg). On day 5, and 5% glycerol. Lysis buffer contained protease inhibitors (Sigma) and phos-
rats and mice received a morning injection of morphine (rats, 45 mg/kg; mice, phatase inhibitors (GBiosciences). Total protein was measured using a Pierce
50 mg/kg) and 2 h later naloxone (2 mg/kg, naloxone hydrochloride dihydrate, BCA Protein Assay Kit (Thermo Scientific). Samples were heated at 95 °C
Sigma) to rapidly induce opiate withdrawal. Control rats and mice received for 5 min in loading buffer (350 mM Tris, 30% glycerol, 1.6% SDS, 1.2%
equivalent volumes of 0.9% saline and were challenged with naloxone on day bromophenol blue, 6% β-mercaptoethanol) then electrophoresed on a pre-
5. Signs of withdrawal were recorded as previously described29. Jumping, teeth cast SDS gel (4–12% Tris-HCl, Bio-Rad) and transferred onto a nitrocellulose
chattering, wet-dog shakes, headshakes and grooming behaviors were evalu- membrane. After blocking, membranes were incubated with rabbit antibody
ated at 5-min intervals for a total test period of 30 min, and a standardized to Panx1 (1:250, Life Technologies, 488100) and mouse antibody to β-actin
score of 0 to 3 was assigned to each behavior. Allodynia, piloerection, saliva- (1:2,000, Sigma-Aldrich, A5316). Membranes were washed and incubated
tion, ejaculation and tremors or twitching were also evaluated, with 1 point for 2 h at room temperature in fluorophore-conjugated secondary antibodies
given to the presence of the behavior during each 5-min interval. All signs were (anti-rabbit- and anti-mouse-conjugated immunoreactivity (IR) dyes 1:5,000,
counted and compiled to yield a cumulative withdrawal score. Rats and mice Mandel Scientific) and quantified by direct detection of secondary antibody
were weighed before and after naloxone challenge to calculate weight loss. In fluorescence at 680 and 800 nm (LICOR Odyssey CLx). Band intensity was
all behavioral studies, experimenters were blind to the drug treatment group quantified using ImageJ, normalized to β-actin and expressed relatively to
and genetic profile of rats and mice. In a subset of experiments, spontaneous control samples.
withdrawal behaviors were assessed in mice 24 h after last morphine or control
injection (on day 6). Isolation of adult mixed neuron–glia culture. Rats and mice were anaesthe-
tized and perfused transcardially with PBS. Spinal cord and (for mice only)
Intrathecal drug administration. In a subset of experiments, rats and brain tissues were isolated and placed in HBSS. After blunt dissociation, spinal
mice were subject to drug administration by intrathecal injection under 2% cord contents were filtered through a 70 µm cell strainer into DMEM con-
isoflurane (vol/vol) by lumbar puncture method as previously described30. taining 10 mM HEPES and 5% FBS. Isotonic Percoll (density 1.23 g/mL) was
Mac1–Sap or Sap (20 µg, Advanced Targeting Systems) was injected on days 1 and added to the cell suspension, followed by a 1.08 g per mL Percoll underlay31.
3 before morning morphine injections. Intrathecal injections of 10panx (10 µg, Samples were spun at 3,000 r.p.m. for 30 min at 20 °C. Following centrifuga-
WRQAAFVDSY, New England Peptide), scrpanx (10 µg, FSVYWAQADR, tion, myelin debris was removed, and the interface between Percoll gradients
New England Peptide) and A-740003 (10 µL of 10 µM, Sigma) were deliv- was collected and transferred into fresh medium. Samples were centrifuged
ered 60 min before naloxone-precipitated withdrawal, and intrathecal apyrase again at 1,350 r.p.m. for 10 min at 4 °C, and the pellet was reconstituted in PBS
(10 units, Sigma) and ARL67156 (10 nmol, Sigma) were delivered 15 min containing 10% FBS (for flow cytometry) or DMEM containing 10% FBS and
before naloxone. ATPγS (100 µM, Roche) was delivered intrathecally imme- 1% penicillin–streptomycin (for live-cell imaging).
diately before naloxone-precipitated withdrawal without the use of isoflu-
rane. All control animals received an equivalent volume of intrathecal 0.9% Flow cytometry. Mixed neuron–glia culture was isolated from adult rat spinal
sterile saline on a timeline identical to that used for treated animals from the cord as described above. Cells were stained with fluorophore-conjugated
same experiment. CD11b/c–PE (1:500 eBioscience, 12-0110-82) and either rabbit antibody to
Panx1 (1:400 Pierce, PA5-34475, and 1:400 Life Technologies) preincubated
Systemic drug administration. Morphine-dependent rats received systemic with fluorophore-conjugated anti-rabbit secondary antibody or fluorphore-
mefloquine (45 mg/kg i.p., Sigma; or 20 mg/kg i.p., Bioblocks) or probenecid conjugated P2X7R–ATTO 633 (1:250 Alomone, APR-008-FR) for 1 h at 20 °C.
doi:10.1038/nm.4281 nature medicine
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
Cell fluorescence was measured by an Attune Acoustic Focusing Cytometer taken at 10-min intervals and represent the average response of all BV-2 cells
(Applied Biosystems). Live single-cell population was gated using forward and in the recorded view from a subset of experiments. To assess Panx1 func-
side scatter plots. CD11b- and Panx1-positive staining were gated using BL2 and tion in adult microglia, neuron–glia mixture culture was isolated from adult
RL1 intensities, respectively, in single stained cells compared to unstained cells. Sprague-Dawley rats treated with saline or morphine for 5 d, or from Cx3cr1-
CreERT2::Panx1flx/flx mice treated with tamoxifen or vehicle for 5 d as described
BV-2 microglia culture. BV-2 microglial-like cells were provided by M. Tsuda above. Once isolated, cells were plated in DMEM containing 10% FBS and 1%
and K. Biber12. Cells were maintained in DMEM (Gibco) containing 5% FBS Pen-Strep and incubated overnight at 37 °C with 5% CO2. Cells were washed
and 1% penicillin–streptomycin (Pen-Strep) at 37°C with 5% CO2 and treated and incubated with DAPI (1:10,000) for 10 min, and then incubated in YO-
with morphine (10 µM), morphine and CTAP (1 µM), DAMGO (1 µM), saline PRO-1 dye (rats) or YO-PRO-3 dye (mice). In rats, microglia were identified
and CTAP, or saline once a day for 5 d. BV-2 microglial-like cells were found to from mixed adult neuronal–glial culture using a fluorophore-conjugated anti-
be free of mycoplasma contamination using MycoFluor Mycoplasma Detection body CD11b/c-PE (1:500, eBioscience), and in mice microglia were identi-
Kit (Molecular Probes). fied by endogenous expression of eYFP. Fluorescence of individual microglia
were recorded for a 5-min baseline period and then for 30 min after BzATP
Calcium imaging. Cells were incubated for 30 min with the fluorescent stimulation (300 µM). Individual traces were taken at 10-min intervals and
Ca2+ indicator dye Fura-2 a.m. (2.5 µM, Molecular Probes) in extracellu- represent responses from a subset of individual microglia. Fluorescence emis-
lar solution (ECS) containing 140 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl2, sion at 30 min was expressed as percentage change from the baseline recorded
10 mM HEPES and 33 mM glucose (pH 7.35, 315 mOsm)32. In a subset of from the same cell.
experiments, mefloquine (40 µM, Sigma or 100 nM, Bioblocks) or probenecid
(1 mM, Life Technologies) were bath applied in ECS after loading of Fura-2 Naloxone-induced ATP release. ATP levels were detected using biolumi-
a.m. and incubated at room temperature for 30 min before BzATP (100 µM) nescence by combining samples with recombinant firefly luciferase and its
stimulation. All experiments were conducted at room temperature using substrate d-luciferin (ATP Determination Kit, Life Technologies). The ATPase
an inverted microscope (Nikon Eclipse Ti C1SI Spectral Confocal), and the inhibitor (ARL67156, 1 µM, Sigma) was added to the ECS or aCSF (in mM: 126
fluorescence of individual microglia was recorded using EasyRatioPro soft- NaCl, 1.6 KCl, 1.1 NaH2PO4, 1.4 MgCl2, 2.4 CaCl2, 26 NaHCO3, 11 glucose)
ware (PTI). Excitation light was generated from a xenon arc lamp and passed to minimize breakdown of ATP, and samples were incubated in medium for
alternatingly through 340- or 380-nm band-pass filters (Omega Optical). The 30 min before naloxone challenge to reduce mechanically induced ATP release.
340/380 fluorescence ratio was calculated after baseline subtraction. Samples were exposed to naloxone (10 µM) for 30 min, then the supernatant
was collected and samples read immediately using a FilterMax F5 plate reader
Generation of Cx3cr1-CreERT2::Panx1flx/flx mice. Mice with microglial-spe- at 28 °C. For experiments with BV-2 microglial-like cultures, cells were incu-
cific deletion of Panx1 were generated using a Cre-loxP system. Panx1flx/flx bated in 10panx (10 µM, New England Peptide), scrpanx (10 µM, New England
homozygote mice33 containing loxP sequences flanking exon 2 of the Panx1 Peptide), probenecid (1 mM, Life Technologies), mefloquine (40 µM, Sigma or
gene were crossed with C57BL6/J mice expressing Cre-ERT2 fusion protein 100 nM, Bioblocks) or ECS for 10 min before naloxone exposure. Final ATP
and enhanced yellow fluorescent protein (eYFP) under the Cx3cr1 promoter measurement was expressed relatively to control samples (saline-treated BV-
(Jax mice: B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT)Litt/WganJ, stock number 021160). 2 cells exposed to ECS) from the same plate. For ATP release in spinal cord
Progeny genotype was screened by PCR, and homozygous Panx1flx/flx and slices, tamoxifen- or vehicle-treated Cx3cr1-CreERT2::Panx1flx/flx mice were
Cx3cr1-CreERT2 mice were bred and backcrossed for 8 generations to yield the perfused with ice-cold oxygenated sucrose-substituted aCSF (s-aCSF in mM:
conditional knockout Cx3cr1-CreERT2::Panx1flx/flx mice. To induce Cre recom- 252 sucrose, 2.5 KCl, 1.5 CaCl2, 6 MgCl2, 10 d-glucose), and the spinal cord
bination, mice were injected i.p. with 1 mg per day tamoxifen (Sigma) for 5 d. rapidly dissected. The lumbar segment of the spinal cord was sliced into 300 µm
Control mice were littermates that received vehicle injections (sunflower oil sections, and incubated in oxygenated 32 °C aCSF for 1 h. Spinal cord slices
with 10% ethanol) for 5 d, while tamoxifen-related effects were controlled for were then transferred to room temperature oxygenated aCSF and exposed to
using Panx1flx/flx littermate mice that received 5 d of tamoxifen injections. naloxone (10 µM). For quantification, ATP release was normalized to total
In the majority of experiments, testing occurred 7 d after final tamoxifen protein of each sample.
injection. In a subset of experiments, behavioral assessment of morphine with-
drawal was conducted 28 d after final tamoxifen injection to control for effects Histological procedures. Rats and mice were anesthetized with pentobarbital
of peripheral Cx3cr1-expressing cells. (Bimeda-MTC Animal Health Inc.) and perfused transcardially with 4% para-
formaldehyde (PFA) (wt/vol). Following dissection, the spinal lumbar segment
YO-PRO dye uptake. After 5 d of morphine or saline treatment, cell culture was post-fixed in 4% PFA, then cryoprotected in 30% sucrose. Spinal cords
medium was removed, and the BV-2 cells were incubated in ECS contain- were sliced at 30 µm into free-floating sections, then incubated overnight at
ing either YO-PRO-1 or YO-PRO-3 dye (2.5 µM, Invitrogen). After a 5-min 4 °C in mouse antibody to CD11b (1:50, CBL1512 EMD Milipore), rat anti-
baseline recording, cells were stimulated with BzATP (150 µM, Sigma), and body to CD11b (1:250, Abcam, ab8878), or rabbit antibody to GFP (1:400,
dye uptake was recorded for 30 min. Cell viability was assessed immediately Life Technologies, A-6465). Sections were then washed and incubated at 4 °C
after 30 min recording by application of ionomycin (1 µM, Sigma). Cells that with fluorochrome-conjugated secondary antibodies (1:1,000, Cy3-conjugated
did not respond to ionomycin were excluded from the analysis. YO-PRO-1 donkey anti-mouse IgG, Jackson Immuno Research; 1:1,000, Cy5-conjugated
dye fluorescence emission (491/509 nm) or YO-PRO-3 dye fluorescent emis- donkey anti-rabbit IgG, Jackson Immuno Research; or 1:2,000 donkey anti-rat
sion (612/631 nm) was detected at 37 °C using a FilterMax F5 plate reader IgG Alexa Fluor 555, Abcam, ab150154). Images were taken using a Nikon
(Molecular Devices). Drugs used included 10panx (10 µM, New England Eclipse Ti C1SI Spectral Confocal microscope and a Nikon A1R Multiphoton
Peptide), scrpanx (10 µM, New England Peptide), naloxone (10 µM, Sigma), microscope. Quantification was performed using ImageJ (NIH) by an experi-
probenecid (1 mM, Life Technologies), and mefloquine (40 µM, Sigma or menter blind to genotype and/or drug treatment.
100 nM, Bioblocks). Drugs were bath applied in ECS containing YO-PRO-1
dye (in the absence of morphine) and incubated at 37 °C for 10 min before cFos immunolabeling. Mouse spinal cord tissue was isolated and sectioned as
BzATP stimulation. For the BV-2 cell experiments, fluorescence emission at described above. Free-floating spinal cord sections were blocked for 10 min with
30 min after BzATP application was calculated as an average of the entire 0.3% H2O2 and then for 5 min with 1% NaBH4. Sections were incubated over-
imaging field as percentage change from baseline, and responses at 30 min night at 4 °C with rabbit antibody to cFos (1:5,000, Abcam, ab7963). Sections
were averaged over multiple independent experiments. Representative images were washed and incubated for 2 h in biotinylated anti-rabbit secondary anti-
of BV-2 YO-PRO-1 dye uptake were taken using EasyRatioPro software (PTI) body (1:1,000; Vector Laboratories) then processed with Vectastain ABC kit
at room temperature using an inverted microscope (Nikon Eclipse Ti C1S1 (Vector Laboratories) and developed for 1 min using 3,3-diaminobenzedine
Spectral Confocal). Individual traces of BV-2 YO-PRO-1 dye uptake were with nickel. Images were taken using an Olympus Virtual Slide System Macro
nature medicine doi:10.1038/nm.4281
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©
Slide Scanner and number of Fos-immunoreactive cells within the superficial using ClampFit 10 software (Molecular Devices). The area of fPSPs relative to
spinal dorsal horn were counted. Imaging and quantification were performed baseline was measured from 0 to 800 ms after the onset of the fPSP.
by an experimenter blind to genotype and drug treatment.
Statistics. All data are presented as mean ± s.e.m., and each data point repre-
Ex vivo spinal cord recordings. Electrically evoked field potentials in the sents an individual animal or experiment. Tests of statistical difference were
superficial dorsal horn were recorded as previously described15. Briefly, ani- performed with GraphPad Prism 6 software using unpaired t-test (two-sided),
mals were anesthetized with urethane (2 g/kg) and perfused transcardially with or ordinary one-way ANOVA with post hoc Bonferroni or Sidak’s test. Time
an ice-cold oxygenated (95% O2, 5% CO2) sucrose-based artificial cerebros- course and daily anti-nociception experiments were analyzed using a two-way
pinal fluid (S-aCSF) solution containing the following (in mM): 252 sucrose, repeated measure ANOVA with post hoc Sidak test. Sample sizes are consistent
2.5 KCl, 6 MgCl2, 1.5 CaCl2, 1.25 NaH2PO4, 26 NaHCO3, 4 kynurenic acid and with those reported in similar studies and provide sufficient power to detect
10 d-glucose. The lumbar spinal column was rapidly removed and immersed changes with the appropriate statistical analysis. Data used for statistical com-
in ice-cold S-aCSF, and the spinal cord was obtained by laminectomy. Spinal parison fit a Gaussian distribution, and variances were equivalent between
cord explants were allowed to recover for 60 min in an immersion chamber groups. For all experiments, a criterion α level was set at 0.05.
containing oxygenated (95% O2, 5% CO2) aCSF (in nM: 126 NaCl, 2.5 KCl,
2 MgCl2, 2 CaCl2, 1.25 NaH2PO4, 26 NaHCO3 and 10 d-glucose) at room Data availability. The data sets generated during and/or analyzed during the cur-
temperature. Post-synaptic field potentials (fPSPs) were recorded via a boro- rent study are available from the corresponding author on reasonable request.
silicate glass electrode inserted into the dorsal side of the spinal cord explant
in the dorsal root entry zone. Electrodes were inserted superficially to a depth
of no more than 125 µm from the dorsal surface of the spinal cord measured
28. Trang, T., Ma, W., Chabot, J.-G., Quirion, R. & Jhamandas, K. Spinal modulation
with an MPC-285 manipulator with MPC-200 controller (Sutter Instrument of calcitonin gene–related peptide by endocannabinoids in the development of
Company). Electrodes had a tip resistance of 3–4 MΩ when filled with aCSF. opioid physical dependence. Pain 126, 256–271 (2006).
fPSPs were evoked by electrical stimulation of the dorsal root using an aCSF- 29. Ferrini, F. et al. Morphine hyperalgesia gated through microglia-mediated disruption
of neuronal Cl− homeostasis. Nat. Neurosci. 16, 183–192 (2013).
filled borosilicate suction electrode placed near the cut end of the dorsal root.
30. Ichikizaki, K., Toya, S. & Hoshino, T. A new procedure for lumbar puncture in the
Field potentials were amplified with a multiclamp 700B amplifier (Molecular mouse (intrathecal injection) preliminary report. Keio J. Med. 28, 165–171
Devices), digitized with a Digidata 1322A (Molecular Devices) and recorded (1979).
using pClamp 10 software (Molecular Devices). Data were filtered during 31. Oyebamiji, A.I. et al. Characterization of migration parameters on peripheral and
central nervous system T cells following treatment of experimental allergic
acquisition with a low-pass filter set at 1.6 kHz and sampled at 10 kHz. Test
encephalomyelitis with CRYAB. J. Neuroimmunol. 259, 66–74 (2013).
stimuli were presented every 60 s to evoke fPSPs, and baseline was determined 32. Trang, T., Beggs, S., Wan, X. & Salter, M.W. P2X4-receptor-mediated synthesis and
as a 30-min period of stable responses (less than 15% variability). After a release of brain-derived neurotrophic factor in microglia is dependent on calcium
stable baseline was observed, naloxone (10 µM) was applied via bath or LTP and p38-mitogen-activated protein kinase activation. J. Neurosci. 29, 3518–3528
(2009).
was evoked by stimulation at 2 Hz for 2 min with a 25% higher intensity than
33. Weilinger, N.L., Tang, P.L. & Thompson, R.J. Anoxia-induced NMDA receptor
baseline stimulation, after which stimulation intensity was returned to baseline activation opens pannexin channels via Src family kinases. J. Neurosci. 32,
levels and test pulses were again delivered once per minute. Data were analyzed 12579–12588 (2012).
doi:10.1038/nm.4281 nature medicine
.devreser
sthgir
llA
.erutaN
regnirpS
fo
trap
,.cnI
,aciremA
erutaN
7102
©